Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma

Phase Ib Study Evaluating the Safety and Efficacy of Intratumoral Agonistic Anti-CD40 (Selicrelumab) in Combination With Anti-PDL1 (Atezolizumab) in Patients With Refractory or Relapsed B Cell Lymphoma

This is a multicenter, open, dose escalation phase Ib trial of intratumoral agonistic anti-CD40 Ab (Selicrelumab intratumoral every 3 weeks for 3 cycles) in combination with anti-PDL1 Ab (Atezolizumab 1200mg intravenous every 3 weeks) in patients with refractory or relapsed B cell lymphoma

Study Overview

• Status: Terminated
• Conditions: Refractory B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma
• Intervention / Treatment: Drug: Selicrelumab; Drug: Atezolizumab

• Study Type: Interventional
• Enrollment (Actual): 4
• Phase: Phase 1

Contacts and Locations

Study Locations

• France
  • Créteil, France
    • APHP - Hopital Henri Mondor
  • Montpellier, France
    • CHU de Montpellier
  • Pierre-Bénite, France
    • Hospices Civils de Lyon - Centre Hospitalier Lyon Sud
  • Rennes, France
    • CHU de Rennes - Hôpital Pontchaillou
  • Villejuif, France
    • Institut Gustave Roussy

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Aged 18 and older
2. Histologically confirmed diagnosis of recurrent or refractory B-non-Hodgkin's lymphoma (NHL)

3. At least one injectable lesion:

   i) at least one nodal lesion amenable to intratumoral injection and biopsy (including deep lesions accessible by interventional radiology either under US or CT-scan guidance). The first injected lesion should be of at least 2 x 1.5 cm in diameter. The subsequent lesions to be injected should be ≥1.5 cm in diameter. Extra nodal lesions will not be considered as injectable lesion.

   ii) OR One cutaneous lesion of at least ≥ 1 cm in diameter. Other extra nodal lesion will not be considered as injectable lesion.

4. Patient must have a 18-F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) avid lymphoma that can be followed by positron emission tomography (PET).
5. Bi-dimensionally measurable disease defined by at least one measurable lesion according to Lugano criteria, with at least 1cm in its shortest diameter and 1.5cm in largest diameter (different from the lesion that will be injected)
6. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1
7. Signed written informed consent
8. Life expectancy ≥ 3 months
9. Patients must have recovered to ≤ grade 1 from all toxicities related to prior treatments excluding alopecia.
10. Patients must be naïve from immunotherapy with anti-PD1/PDL1 or agonistic anti-CD40 therapy

11. Adequate laboratory parameters:

    • Hb ≥ 9 g/dl
    • absolute neutrophil count (ANC) ≥ 1000/μL
    • Platelet count ≥ 50,000/μL
    • Total bilirubin < 2.5 times the institutional upper limit of normal (ULN) (3.5 x ULN if liver involvement)
    • Hepatic enzymes (aspartate aminotransferase (AST), alanine aminotransferase (ALT) ) ≤ 2.5 x ULN (5 x ULN if liver involvement)
    • Serum creatinine < 2.0 x ULN or creatinine clearance >50 mL/mn
    • International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) >1.5 × ULN
12. Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test within 72 hours prior to the start of study drug administration.

13. Persons of reproductive potential must agree to use an adequate method of contraception throughout treatment and for at least 6 months after study drug is stopped.

    *Highly effective method includes: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation 1 (oral/ intravaginal/ transdermal); progestogen-only hormonal contraception associated with inhibition of ovulation 1 (oral/injectable/implantable); intrauterine device (IUD); intrauterine hormone-releasing system (IUS); bilateral tubal occlusion; vasectomised partner; sexual abstinence

14. Patient covered by any social security system (France)
15. Patient who understands and speaks one of the country official language

Exclusion Criteria:

1. Immature B cell malignancies (B-acute lymphoblastic leukemia (ALL), Burkitt lymphoma) and T-cell lymphomas
2. History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins or known hypersensitivity to Chinese hamster ovarian (CHO) cell products or any component of the Atezolizumab formulation. Patients with a known allergy to either of the drugs individually
3. Use of any standard or experimental anti-cancer drug therapy within 4 weeks prior to the first scheduled treatment dose (C1D1).
4. History of treatment with anti-PD1 or anti-PDL1.

5. Significant immunosuppression from:

   • Concurrent, recent (≤ 2 weeks ago) or anticipated treatment with systemic corticosteroids at dose >10mg/day of prednisolone (or equivalent)
   • Other immunosuppressive medications such as methotrexate, cyclosporine, azathioprine
   • Any immunosuppressive condition such as common variable hypogammaglobulinemia
6. Myocardial infarction within 6 months prior to first study drug, active cardiac ischemia or New York Heart Association (NYHA) Grade III or IV heart failure, severe arrhythmia, unstable arrhythmias, or unstable angina) or pulmonary disease (including uncontrolled obstructive pulmonary disease and history of bronchospasm or other according to investigator's decision)
7. left ventricular ejection fraction (LVEF) < 45% as determined by echocardiography or multiple uptake gated acquisition (MUGA) scan
8. Clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
9. Prior history of other cancer other than lymphoma within 2 years (except basal cell carcinoma, in situ squamous and non-squamous cell carcinomas completely resected (R0) and prostate cancers with normal results for more than 6 months)
10. Recent (< 1 month ago) clinically significant infection, active tuberculosis or antibiotics therapy
11. Central nervous system involvement with lymphoma, including parenchymal and leptomeningeal disease. Patients with asymptomatic focal epiduritis on imaging might be included with the Sponsor's approval.
12. Ongoing or history of autoimmune disease, including active non-infectious pneumonitis, with the exception of alopecia, vitiligo, auto-immune endocrine deficiency with stable hormone replacement therapy, controlled skin eczema and stable asymptomatic and treated asthma. Patients with severe auto-immune disease in one of their parents, siblings, or children will not be eligible.
13. Psychiatric, other medical illness or other condition that in the opinion of the PI prevents compliance with study procedures or ability to provide valid informed consent
14. Use of anti-coagulant agents or history a significant bleeding diathesis. If a superficial lymph node or subcutaneous mass is to be injected, patients on agents such as non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, or clopidogrel are eligible and these agents do not have to be withheld. For procedures with moderate or significant risk of bleeding, long-acting agents such as aspirin or clopidogrel should be discussed with the Sponsor and may need to be discontinued before Selicrelumab therapy. Patients under preventive dose of low molecular weight heparin (LMWH) are eligible if they can stop their treatment 24h prior the IT injection and restart 24h after the injection. No anticoagulant restriction for patients with injected lesions being superficial tumor lesions eligible for at least 5mn mechanical compression after tumor biopsy & injections (as in routine interventional radiology practice).
15. Subcapsular liver tumor lesions of tumor encased vessels or not eligible for intratumoral biopsies or injections.
16. Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during Atezolizumab treatment or within 5 months after the last dose of Atezolizumab
17. Prior allogeneic hematopoietic stem cell transplantation
18. Patients who have undergone a solid organ transplant
19. Documented infection with HIV
20. Positive serology to hepatitis B. Patients with previous and cured infections are not eligible. Patients who are seropositive due to a history of hepatitis B vaccine are eligible.
21. History or presence of an abnormal ECG that is clinically significant in the investigator's opinion, including complete left bundle branch block, second- or third degree heart block, or evidence of prior myocardial infarction
22. Person deprived of his/her liberty by a judicial or administrative decision
23. Person hospitalized without consent
24. Adult person under legal protection
25. Adult person unable to provide informed consent because of intellectual impairment, any serious medical condition, laboratory abnormality or psychiatric illness
26. Pregnant or nursing women

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: treatment	Drug: Selicrelumab; escalated dose in intratumoral injection, every 3 weeks, for 3 cycles; Drug: Atezolizumab; 1200mg IV every 3 week until progression or relapse for maximum 1 year; Other Names: Tecentriq

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
optimal dose of intratumoral Selicrelumab in combination with flat doses of Atezolizumab IV	21 days (1 cycle)

Secondary Outcome Measures

Outcome Measure	Time Frame
overall survival (OS)	2 years
complete metabolic response rate (CMR)	2 months
complete metabolic response rate (CMR)	4 months
complete metabolic response rate (CMR)	8 months
complete metabolic response rate (CMR)	13 months
overall metabolic response rate (OMR)	2 months
overall metabolic response rate (OMR)	4 months
overall metabolic response rate (OMR)	8 months
overall metabolic response rate (OMR)	13 months
Best overall metabolic response (BOMR)	4 months
duration of response (DOR)	2 years
progression free survival (PFS)	2 years
Number of serious adverse event (SAE)	16 months

Collaborators and Investigators

• Sponsor: The Lymphoma Academic Research Organisation
• Collaborators: Roche Pharma AG
• Investigators: Study Chair: Roch HOUOT, Pr, Chu Rennes

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 4, 2019
• Primary Completion (ACTUAL): April 7, 2021
• Study Completion (ACTUAL): April 7, 2021

Study Registration Dates

• First Submitted: March 26, 2019
• First Submitted That Met QC Criteria: March 26, 2019
• First Posted (ACTUAL): March 27, 2019

Study Record Updates

• Last Update Posted (ACTUAL): July 26, 2021
• Last Update Submitted That Met QC Criteria: July 23, 2021
• Last Verified: July 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Antineoplastic Agents; Atezolizumab
• Other Study ID Numbers: ITSELF

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No